Abstract
Vascular smooth muscle cells (VSMCs) contraction can be evoked by the rise of cytosolic [Ca2+] owing to transmembrane Ca2+ influx or sarcoplasmic reticulum (SR) Ca2+ release. Although the classical ionotropic role of voltagedependent (L-type) Ca2+ channels (VGCCs) is known, we review here data suggesting a new metabotropic function of VGCCs in vascular smooth muscle cells. VGCCs can trigger Ca2+ release from the SR in the absence of extracellular Ca2+. During depolarization, VGCCs can activate G proteins and phospholipase C (PLC)/inositol 1,4,5-trisphosphate (InsP3) pathway leading to Ca2+ release and arterial contraction. This new metabotropic role of VGCCs, referred as calcium channel-induced Ca2+ release (CCICR), has a major role in tonic VSM contractility, as it links sustained membrane depolarization and Ca2+ channel activation with metabotropic Ca2+ release from the sarcoplasmic reticulum (SR) and tonic smooth muscle contraction. This new role of VGCCs could have a wide functional relevance for the pathogenesis of vasospasms mediated by membrane depolarization and vasoactive agents that can activate VGCCs. Precise understanding of CCICR could help to optimize pharmacological treatments for clinical conditions where Ca2+ channels antagonists are recommended.
Keywords: Vascular smooth muscle, L-type Ca2+ channels, sarcoplasmic reticulum, depolarization-induced Ca2+ release, arterial contraction.
Current Vascular Pharmacology
Title:A New Metabotropic Role for L-type Ca2+ Channels in Vascular Smooth Muscle Contraction
Volume: 11 Issue: 4
Author(s): Juan Urena, Miguel Fernandez-Tenorio, Cristina Porras-Gonzalez, Patricia Gonzalez-Rodriguez, Antonio Castellano and Jose Lopez-Barneo
Affiliation:
Keywords: Vascular smooth muscle, L-type Ca2+ channels, sarcoplasmic reticulum, depolarization-induced Ca2+ release, arterial contraction.
Abstract: Vascular smooth muscle cells (VSMCs) contraction can be evoked by the rise of cytosolic [Ca2+] owing to transmembrane Ca2+ influx or sarcoplasmic reticulum (SR) Ca2+ release. Although the classical ionotropic role of voltagedependent (L-type) Ca2+ channels (VGCCs) is known, we review here data suggesting a new metabotropic function of VGCCs in vascular smooth muscle cells. VGCCs can trigger Ca2+ release from the SR in the absence of extracellular Ca2+. During depolarization, VGCCs can activate G proteins and phospholipase C (PLC)/inositol 1,4,5-trisphosphate (InsP3) pathway leading to Ca2+ release and arterial contraction. This new metabotropic role of VGCCs, referred as calcium channel-induced Ca2+ release (CCICR), has a major role in tonic VSM contractility, as it links sustained membrane depolarization and Ca2+ channel activation with metabotropic Ca2+ release from the sarcoplasmic reticulum (SR) and tonic smooth muscle contraction. This new role of VGCCs could have a wide functional relevance for the pathogenesis of vasospasms mediated by membrane depolarization and vasoactive agents that can activate VGCCs. Precise understanding of CCICR could help to optimize pharmacological treatments for clinical conditions where Ca2+ channels antagonists are recommended.
Export Options
About this article
Cite this article as:
Urena Juan, Fernandez-Tenorio Miguel, Porras-Gonzalez Cristina, Gonzalez-Rodriguez Patricia, Castellano Antonio and Lopez-Barneo Jose, A New Metabotropic Role for L-type Ca2+ Channels in Vascular Smooth Muscle Contraction, Current Vascular Pharmacology 2013; 11 (4) . https://dx.doi.org/10.2174/1570161111311040012
DOI https://dx.doi.org/10.2174/1570161111311040012 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nanoparticle Based Treatment for Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Pharmacological, Immunological, and Gene Targeting of the Renin-Angiotensin System for Treatment of Cardiovascular Disease
Current Pharmaceutical Design Genome Study of Kidney Disease in the Age of Post Genome-Sequencing
Endocrine, Metabolic & Immune Disorders - Drug Targets TP Receptor as a Therapeutic Target in Atherosclerosis and Related Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Protein Z and Ischemic Stroke
Vascular Disease Prevention (Discontinued) Heart Failure Pharmacotherapy and Supports in the Elderly - A Short Review
Current Cardiology Reviews Calcium Channel Blockers in Obesity-Related Hypertension
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Effect of First-in-Class Small Molecule RhoA Inhibitor, HL07, on the Phenylephrine-induced Artery Contraction
Current Pharmaceutical Design The Clinical Trials of Mesenchymal Stem Cell Therapy in Skin Diseases: An Update and Concise Review
Current Stem Cell Research & Therapy Therapeutic Promises of Chlorogenic Acid with Special Emphasis on its Anti-Obesity Property
Current Molecular Pharmacology Osteoporosis and its Association with Non-Gonadal Hormones Involved in Hypertension, Adiposity and Hyperglycaemia
Current Drug Targets New Challenges for ACE-Inhibitors in Vascular Diseases
Drug Design Reviews - Online (Discontinued) Pediatric Obesity Epidemic: Problem and Solutions
Current Pharmaceutical Design Malignant Hypertension: A Rare Problem or is it Underdiagnosed?
Current Vascular Pharmacology Population Approaches for Detecting Glucose Disorders
Current Diabetes Reviews Recreational Drug Misuse and Stroke
Current Drug Abuse Reviews Vitamin D and Vitamin D Receptor: New Insights in the Treatment of Hypertension
Current Protein & Peptide Science Imidazoline Receptor Agonists for Managing Hypertension May Hold Promise for Treatment of Intracerebral Hemorrhage
Current Molecular Medicine Therapeutic Apheresis in Metabolic Syndrome
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) A Green and Efficient One-pot Synthesis of 1,2,3-Trisubstituted Pyrroles via Iodine-catalyzed Tandem Reaction
Letters in Organic Chemistry